Cargando…

Knockdown of NAT12/NAA30 reduces tumorigenic features of glioblastoma-initiating cells

BACKGROUND: Glioblastoma (GBM) is the most common primary brain malignancy and confers a dismal prognosis. GBMs harbor glioblastoma-initiating cells (GICs) that drive tumorigenesis and contribute to therapeutic resistance and tumor recurrence. Consequently, there is a strong rationale to target this...

Descripción completa

Detalles Bibliográficos
Autores principales: Mughal, Awais A., Grieg, Zanina, Skjellegrind, Håvard, Fayzullin, Artem, Lamkhannat, Mustapha, Joel, Mrinal, Ahmed, M. Shakil, Murrell, Wayne, Vik-Mo, Einar O., Langmoen, Iver A., Stangeland, Biljana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546247/
https://www.ncbi.nlm.nih.gov/pubmed/26292663
http://dx.doi.org/10.1186/s12943-015-0432-z
_version_ 1782386886293061632
author Mughal, Awais A.
Grieg, Zanina
Skjellegrind, Håvard
Fayzullin, Artem
Lamkhannat, Mustapha
Joel, Mrinal
Ahmed, M. Shakil
Murrell, Wayne
Vik-Mo, Einar O.
Langmoen, Iver A.
Stangeland, Biljana
author_facet Mughal, Awais A.
Grieg, Zanina
Skjellegrind, Håvard
Fayzullin, Artem
Lamkhannat, Mustapha
Joel, Mrinal
Ahmed, M. Shakil
Murrell, Wayne
Vik-Mo, Einar O.
Langmoen, Iver A.
Stangeland, Biljana
author_sort Mughal, Awais A.
collection PubMed
description BACKGROUND: Glioblastoma (GBM) is the most common primary brain malignancy and confers a dismal prognosis. GBMs harbor glioblastoma-initiating cells (GICs) that drive tumorigenesis and contribute to therapeutic resistance and tumor recurrence. Consequently, there is a strong rationale to target this cell population in order to develop new molecular therapies against GBM. Accumulating evidence indicates that Nα-terminal acetyltransferases (NATs), that are dysregulated in numerous human cancers, can serve as therapeutic targets. METHODS: Microarrays were used to study the expression of several NATs including NAT12/NAA30 in clinical samples and stem cell cultures. The expression of NAT12/NAA30 was analyzed using qPCR, immunolabeling and western blot. We conducted shRNA-mediated knockdown of NAT12/NAA30 gene in GICs and studied the effects on cell viability, sphere-formation and hypoxia sensitivity. Intracranial transplantation to SCID mice enabled us to investigate the effects of NAT12/NAA30 depletion in vivo. Using microarrays we identified genes and biochemical pathways whose expression was altered upon NAT12/NAA30 down-regulation. RESULTS: While decreased expression of the distal 3’UTR of NAT12/NAA30 was generally observed in GICs and GBMs, this gene was strongly up-regulated at the protein level in GBM and GICs. The increased protein levels were not caused by increased levels of the steady state mRNA but rather by other mechanisms. Also, shorter 3’UTR of NAT12/NAA30 correlated with poor survival in glioma patients. As well, we observed previously not described nuclear localization of this typically cytoplasmic protein. When compared to non-silencing controls, cells featuring NAT12/NAA30 knockdown exhibited reduced cell viability, sphere-forming ability, and mitochondrial hypoxia tolerance. Intracranial transplantation showed that knockdown of NAT12/NAA30 resulted in prolonged animal survival. Microarray analysis of the knockdown cultures showed reduced levels of HIF1α and altered expression of several other genes involved in the hypoxia response. Furthermore, NAT12/NAA30 knockdown correlated with expressional dysregulation of genes involved in the p53 pathway, ribosomal assembly and cell proliferation. Western blot analysis revealed reduction of HIF1α, phospho-MTOR(Ser2448) and higher levels of p53 and GFAP in these cultures. CONCLUSION: NAT12/NAA30 plays an important role in growth and survival of GICs possibly by regulating hypoxia response (HIF1α), levels of p-MTOR (Ser2448) and the p53 pathway. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-015-0432-z) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-4546247
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-45462472015-08-23 Knockdown of NAT12/NAA30 reduces tumorigenic features of glioblastoma-initiating cells Mughal, Awais A. Grieg, Zanina Skjellegrind, Håvard Fayzullin, Artem Lamkhannat, Mustapha Joel, Mrinal Ahmed, M. Shakil Murrell, Wayne Vik-Mo, Einar O. Langmoen, Iver A. Stangeland, Biljana Mol Cancer Research BACKGROUND: Glioblastoma (GBM) is the most common primary brain malignancy and confers a dismal prognosis. GBMs harbor glioblastoma-initiating cells (GICs) that drive tumorigenesis and contribute to therapeutic resistance and tumor recurrence. Consequently, there is a strong rationale to target this cell population in order to develop new molecular therapies against GBM. Accumulating evidence indicates that Nα-terminal acetyltransferases (NATs), that are dysregulated in numerous human cancers, can serve as therapeutic targets. METHODS: Microarrays were used to study the expression of several NATs including NAT12/NAA30 in clinical samples and stem cell cultures. The expression of NAT12/NAA30 was analyzed using qPCR, immunolabeling and western blot. We conducted shRNA-mediated knockdown of NAT12/NAA30 gene in GICs and studied the effects on cell viability, sphere-formation and hypoxia sensitivity. Intracranial transplantation to SCID mice enabled us to investigate the effects of NAT12/NAA30 depletion in vivo. Using microarrays we identified genes and biochemical pathways whose expression was altered upon NAT12/NAA30 down-regulation. RESULTS: While decreased expression of the distal 3’UTR of NAT12/NAA30 was generally observed in GICs and GBMs, this gene was strongly up-regulated at the protein level in GBM and GICs. The increased protein levels were not caused by increased levels of the steady state mRNA but rather by other mechanisms. Also, shorter 3’UTR of NAT12/NAA30 correlated with poor survival in glioma patients. As well, we observed previously not described nuclear localization of this typically cytoplasmic protein. When compared to non-silencing controls, cells featuring NAT12/NAA30 knockdown exhibited reduced cell viability, sphere-forming ability, and mitochondrial hypoxia tolerance. Intracranial transplantation showed that knockdown of NAT12/NAA30 resulted in prolonged animal survival. Microarray analysis of the knockdown cultures showed reduced levels of HIF1α and altered expression of several other genes involved in the hypoxia response. Furthermore, NAT12/NAA30 knockdown correlated with expressional dysregulation of genes involved in the p53 pathway, ribosomal assembly and cell proliferation. Western blot analysis revealed reduction of HIF1α, phospho-MTOR(Ser2448) and higher levels of p53 and GFAP in these cultures. CONCLUSION: NAT12/NAA30 plays an important role in growth and survival of GICs possibly by regulating hypoxia response (HIF1α), levels of p-MTOR (Ser2448) and the p53 pathway. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s12943-015-0432-z) contains supplementary material, which is available to authorized users. BioMed Central 2015-08-21 /pmc/articles/PMC4546247/ /pubmed/26292663 http://dx.doi.org/10.1186/s12943-015-0432-z Text en © Mughal et al. 2015 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Mughal, Awais A.
Grieg, Zanina
Skjellegrind, Håvard
Fayzullin, Artem
Lamkhannat, Mustapha
Joel, Mrinal
Ahmed, M. Shakil
Murrell, Wayne
Vik-Mo, Einar O.
Langmoen, Iver A.
Stangeland, Biljana
Knockdown of NAT12/NAA30 reduces tumorigenic features of glioblastoma-initiating cells
title Knockdown of NAT12/NAA30 reduces tumorigenic features of glioblastoma-initiating cells
title_full Knockdown of NAT12/NAA30 reduces tumorigenic features of glioblastoma-initiating cells
title_fullStr Knockdown of NAT12/NAA30 reduces tumorigenic features of glioblastoma-initiating cells
title_full_unstemmed Knockdown of NAT12/NAA30 reduces tumorigenic features of glioblastoma-initiating cells
title_short Knockdown of NAT12/NAA30 reduces tumorigenic features of glioblastoma-initiating cells
title_sort knockdown of nat12/naa30 reduces tumorigenic features of glioblastoma-initiating cells
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4546247/
https://www.ncbi.nlm.nih.gov/pubmed/26292663
http://dx.doi.org/10.1186/s12943-015-0432-z
work_keys_str_mv AT mughalawaisa knockdownofnat12naa30reducestumorigenicfeaturesofglioblastomainitiatingcells
AT griegzanina knockdownofnat12naa30reducestumorigenicfeaturesofglioblastomainitiatingcells
AT skjellegrindhavard knockdownofnat12naa30reducestumorigenicfeaturesofglioblastomainitiatingcells
AT fayzullinartem knockdownofnat12naa30reducestumorigenicfeaturesofglioblastomainitiatingcells
AT lamkhannatmustapha knockdownofnat12naa30reducestumorigenicfeaturesofglioblastomainitiatingcells
AT joelmrinal knockdownofnat12naa30reducestumorigenicfeaturesofglioblastomainitiatingcells
AT ahmedmshakil knockdownofnat12naa30reducestumorigenicfeaturesofglioblastomainitiatingcells
AT murrellwayne knockdownofnat12naa30reducestumorigenicfeaturesofglioblastomainitiatingcells
AT vikmoeinaro knockdownofnat12naa30reducestumorigenicfeaturesofglioblastomainitiatingcells
AT langmoenivera knockdownofnat12naa30reducestumorigenicfeaturesofglioblastomainitiatingcells
AT stangelandbiljana knockdownofnat12naa30reducestumorigenicfeaturesofglioblastomainitiatingcells